News
- 2018/11/28
- Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK” Obtained Approval for Additional Indication and Dosage & Administration of Breast Cancer with HER2 Overexpression
- 2018/08/20
- Nippon Kayaku launches Trastuzumab BS for I.V. Infusion 60mg “NK”・150mg “NK”, a humanized anti-human HER2 monoclonal Antibody
- 2018/03/23
- Nippon Kayaku Receives Manufacture and Marketing Approval in Japan for Biosimilar of Trastuzumab Monoclonal Antibody